Company NewsHomepage NewsNews Highlight Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC JIANGSU, China, April 26, 2024 — Ractigen Therapeutics, a leader in the development of small…ractigenApril 26, 2024
Company News Ractigen Announces First Patient Dosed in the Phase I Clinical Trial of RAG-01 for NMIBC JIANGSU, China, April 3, 2024 – Ractigen Therapeutics, a pioneer in small activating RNA (saRNA) therapeutics,…ractigenApril 3, 2024
Presentations Therapeutic Development of saRNA for Duchenne Muscular Dystrophy by Targeted Activation of Utrophin (Poster) Event: 2024 TIDES Asia Conference (Tokyo Japan) View PosterractigenMarch 21, 2024
Company News Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders Suzhou, China – January 29, 2024 – Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the…ractigenJanuary 29, 2024
Company NewsHomepage News Ractigen Therapeutics Advances into Clinical Stage with Groundbreaking saRNA Drug, RAG-01 JIANGSU, China, Dec. 06, 2023 — Ractigen Therapeutics, a leader in the field of small…ractigenDecember 6, 2023
Company News Ractigen Therapeutics Announces Dosing of First Patient in First in Human Trial of RAG-17 for the Treatment of SOD1-ALS Study aims to evaluate the safety and feasibility of RAG-17 in human patients and clinically…ractigenJune 10, 2023
News Highlight Ractigen Therapeutics Receives FDA Orphan Drug Designation for the novel oligonucleotide conjugate RAG-17 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Jiangsu, China — Ractigen Therapeutics announced today that the U.S. Food and Drug Administration (FDA)…ractigenMarch 3, 2023